Effects of gemcitabine on radiosensitization, apoptosis, and Bcl-2 and Bax protein expression in human pancreatic cancer xenografts in nude mice

Genetics and Molecular Research

Volumn 14, Issue 4, 2015, Pages 15587-15596

  Shen, Z T ^a   Wu, X H ^a   Wang, L ^a   Li, B ^a   Zhu, X X ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Gemcitabine; Pancreatic cancer; Radiosensitization; Radiotherapy

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; GEMCITABINE; PROTEIN BAX; PROTEIN BCL 2; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; TUNEL ASSAY; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION; GENETICS; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84979762834     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.December.1.10     Document Type: Article

References (22)

1. Brullé L, Vandamme M, Riès D, Martel E, et al. (2012). Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model. PLoS One 7: e52653.
2. Fennell DA, Chacko A and Mutti L (2008). BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 27: 1189-1197.
3. Gomez DR, Tucker SL, Martel MK, Mohan R, et al. (2012). Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 84: 1010-1016.
4. Hackert T and Büchler MW (2013). Pancreatic cancer: advances in treatment, results and limitations. Dig. Dis. 31: 51-56.
5. Herman JM, Fan KY, Wild AT, Hacker-Prietz A, et al. (2013). Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 86: 678-685.
6. Hersey P and Zhang XD (2003). Overcoming resistance of cancer cells to apoptosis. J. Cell Physiol. 196: 9-18.
7. Katz D, Ito E and Liu FF (2009). On the path to seeking novel radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys. 73: 988-996.
8. Kvols LK (2005). Radiation sensitizers: A selective review of targeting DNA and non-DNA targets. J. Nucl. Med. 46: 187S-190S.
9. Mason KA, Milas L, Hunter NR, Elshaikh M, et al. (1999). Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys. 44: 1125-1135.
10. Morgan MA, Parsels LA, Zhao L, Parsels JD, et al. (2010). Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70: 4972-4981.
11. Onishi H, Araki T, Shirato H, Nagata Y, et al. (2004). Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101: 1623-1631.
12. Pannala R, Leirness JB, Bamlet WR, Basu A, et al. (2008). Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134: 981-987.
13. Pauwels B, Korst AE, Lardon F and Vermorken JB (2005). Combined modality therapy of gemcitabine and radiation. Oncologist 10: 34-51.
14. Plunkett W, Huang P and Gandhi V (1995a). Preclinical characteristics of gemcitabine. Anticancer Drugs 6: 7-13.
15. Plunkett W, Huang P, Xu YZ, Heinemann V, et al. (1995b). Gemcitabine: metabolism, mechanism of actions, and self-potentiation. Semin. Oncol. 22: 3-10.
16. Rübe CE, Wilfert F, Uthe D, König J, et al. (2004). Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother. Oncol. 72: 231-241.
17. Shewach DS and Lawrence TS (1996). Radiosensitization of human solid tumor cell lines with gemcitabine. Semin. Oncol. 23: 65-71.
18. Shewach DS and Lawrence TS (2007). Antimetabolite radiosensitizers. J. Clin. Oncol. 25: 4043-4050.
19. Trisciuoglio D, Gabellini C, Desideri M, Ziparo E et al. (2010). Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One 5: e11772.
20. Trisciuoglio D, Gabellini C, Desideri M, Ragazzoni Y, et al. (2011). Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. Cell Death Differ. 18: 1024-1035.
21. Van Laethem JL, Hammel P, Mornex F, Azria D, et al. (2010). Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/ GERCOR phase II study. J. Clin. Oncol. 28: 4450-4456.
22. Zinner RG, Komaki R, Cox JD, Glisson BS, et al. (2009). Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 73: 119-127.